JULIA WITTE: Open Payments
NPI 1053960807 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$412 in 17 payments from 9 companies in 2025. Trend: 2023 $284 · 2024 $286 · 2025 $412
Food & beverage: $312Education: $100
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 8 | $250 |
| Neurocrine BioSciences, Inc. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| ABBVIE INC. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Novo Nordisk Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Merck Sharp & Dohme LLC | 1 | $14 |
Products named: Veozah, INGREZZA, REXULTI, ZENPEP, VRAYLAR, MOUNJARO, Saxenda, AUSTEDO XR.
Industry payments across MI — which companies pay providers there.
